Cargando…
Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488774/ https://www.ncbi.nlm.nih.gov/pubmed/36126084 http://dx.doi.org/10.1371/journal.pone.0274876 |
_version_ | 1784792733823533056 |
---|---|
author | Shim, Yoon-Bo Byun, Joo-Young Lee, Ju-Yong Lee, Eui-Kyung Park, Mi-Hai |
author_facet | Shim, Yoon-Bo Byun, Joo-Young Lee, Ju-Yong Lee, Eui-Kyung Park, Mi-Hai |
author_sort | Shim, Yoon-Bo |
collection | PubMed |
description | Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This was a retrospective cohort analysis of South Korean health insurance review and assessment claims data. Patients with stage IIIB or IV NSCLC were identified (March 1, 2013 to February 28, 2018). We compared their two-year and per-patient-per-month (PPPM) healthcare costs and resource utilization with 1:3 propensity score-matched patients without the condition. A generalized linear model was used to estimate the impact of BM and other covariates on healthcare costs. After propensity score matching with the 33 402 newly diagnosed cases of stage IIIB or IV NSCLC, 3435 and 10 305 patients were classified as having or not having BM, respectively. Mean healthcare costs were significantly greater in patients with BM for both the two years (US$ 44 692 vs. US$ 32 230, p < .0001) and PPPM (US$ 3510 vs. US$ 2573, p < .0001). The length of hospital stay was longer in patients with BM (79.15 vs. 69.41 days for two years, p < .0001; 7.69 vs. 6.86 days PPPM, p < .0001), and patients with BM had more outpatient visits (50.61 vs. 46.43 times for two years, p < .0001; 3.64 vs. 3.40 times PPPM costs, p < .0001). The costs of drugs, radiology/radiotherapy, and admission comprised the majority of PPPM costs and were higher in patients with BM. The generalized linear model analysis suggested that patients with BM had significantly increased healthcare costs (by 1.29-fold, 95% confidence interval 1.26–1.32). BM is a significant economic burden for patients with NSCLC. Therefore, it is important to prevent BM in patients with NSCLC to reduce their economic burden. |
format | Online Article Text |
id | pubmed-9488774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94887742022-09-21 Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data Shim, Yoon-Bo Byun, Joo-Young Lee, Ju-Yong Lee, Eui-Kyung Park, Mi-Hai PLoS One Research Article Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This was a retrospective cohort analysis of South Korean health insurance review and assessment claims data. Patients with stage IIIB or IV NSCLC were identified (March 1, 2013 to February 28, 2018). We compared their two-year and per-patient-per-month (PPPM) healthcare costs and resource utilization with 1:3 propensity score-matched patients without the condition. A generalized linear model was used to estimate the impact of BM and other covariates on healthcare costs. After propensity score matching with the 33 402 newly diagnosed cases of stage IIIB or IV NSCLC, 3435 and 10 305 patients were classified as having or not having BM, respectively. Mean healthcare costs were significantly greater in patients with BM for both the two years (US$ 44 692 vs. US$ 32 230, p < .0001) and PPPM (US$ 3510 vs. US$ 2573, p < .0001). The length of hospital stay was longer in patients with BM (79.15 vs. 69.41 days for two years, p < .0001; 7.69 vs. 6.86 days PPPM, p < .0001), and patients with BM had more outpatient visits (50.61 vs. 46.43 times for two years, p < .0001; 3.64 vs. 3.40 times PPPM costs, p < .0001). The costs of drugs, radiology/radiotherapy, and admission comprised the majority of PPPM costs and were higher in patients with BM. The generalized linear model analysis suggested that patients with BM had significantly increased healthcare costs (by 1.29-fold, 95% confidence interval 1.26–1.32). BM is a significant economic burden for patients with NSCLC. Therefore, it is important to prevent BM in patients with NSCLC to reduce their economic burden. Public Library of Science 2022-09-20 /pmc/articles/PMC9488774/ /pubmed/36126084 http://dx.doi.org/10.1371/journal.pone.0274876 Text en © 2022 Shim et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Shim, Yoon-Bo Byun, Joo-Young Lee, Ju-Yong Lee, Eui-Kyung Park, Mi-Hai Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title | Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title_full | Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title_fullStr | Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title_full_unstemmed | Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title_short | Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data |
title_sort | economic burden of brain metastases in non-small cell lung cancer patients in south korea: a retrospective cohort study using nationwide claims data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488774/ https://www.ncbi.nlm.nih.gov/pubmed/36126084 http://dx.doi.org/10.1371/journal.pone.0274876 |
work_keys_str_mv | AT shimyoonbo economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata AT byunjooyoung economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata AT leejuyong economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata AT leeeuikyung economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata AT parkmihai economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata |